FDA to review broader access to restricted peptides in July Peptides are starting to move back into the conversation., After years of restriction under the FDAs 503A Category 2 list, were now seeing momentum toward re evaluation and potential reintroduction FDA to Remove 12 Popular Peptides from the Category 2 Do Not Compound List Frier Levitt FDA Peptide Update 2026: Removal from Do Not Compound List and What It Means for Pharmacies The Sikiric Problem: One Lab, Thirty Years, Zero Trials That Matter FDA to Convene Pharmacy Compounding Advisory Committee in July